StockData

OPKO Health vs Telix Pharmaceuticals

OPK and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OPK and TLX compare

Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus −11.5% for OPKO Health).

Telix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −0.89% compared with −12.4% at OPKO Health.

OPKO Health scores higher on the StockData Score (9 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOPKTLX
Size and price
Market cap$1.2B–
Share price$1.62$8.86
Change, 1 year26.6%−5.2%
Change, 5 years−60.8%–
Beta (5Y)0.361.10
Employees2,2751,120
StockData Score
Total score9 (better)3
Valuation score1 (better)0
Growth score11
Performance score3 (better)1
Health score4 (better)1
Dividend score00
Valuation
P/S2.1×–
P/B1.0×–
EV/EBITDA22.0×–
FCF yield−11.1%–
Fair value$1.55–
Margin of safety−4.7%–
Growth
Revenue growth (TTM)−11.5%55.6% (better)
Revenue growth, 5Y average−15.8%–
Net income growth (TTM)–−121%
EPS growth (TTM)–−122%
Profitability
Gross margin40.8%53.1% (better)
Operating margin−8.2%3.7% (better)
Net margin−12.4%−0.89% (better)
FCF margin−22.8%−5.3% (better)
Return on equity−5.9%–
Return on invested capital−4.0%–
Financial health
Debt / equity0.00–
Net debt / EBITDA−7.195.17 (better)
Interest coverage–0.7×
Current ratio3.35 (better)2.01
Altman Z-score−0.21–
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield3.9%–
Shareholder yield3.9%–
Ownership
Held by institutions27.2%0.94%
Held by insiders43.6%8.3%
Insider net buying, 12 months−$13.2K$1.0M (better)
Short interest, % of float7.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.